Inmigrantes latinos en apuros económicos participan una y otra vez en ensayos clínicos para ganar dinero. No siempre les explican los riesgos para su salud y, cuando algo sale mal, buscar justicia puede ser agónico.
NYT's Katie Thomas shares how she finds and vets stories of real people stung by ever-rising drug prices, and expert panelists provide key context for rounding out coverage.
California's Prop 61 faces strong opposition from the pharmaceutical industry, which has poured at least $109 million into defeating it.
The specialty drug Orkambi, for cystic fibrosis, has a sticker price of $259,000 per year. What's driving these astronomical costs for specialty drugs? And can California's budget cope?
There’s no question that prescription drug prices are skyrocketing in the United States, and consumers aren’t happy about it. What’s more complicated, though, is understanding the complexities of the issue and reporting on what those soaring prices mean for consumers.
The ideas shared at last week's Health Journalism 2014 conference were innovative, provocative, and worth integrating into your daily reporting. Columnist William Heisel shares some of the most compelling lessons learned from this year's gathering.
GlaxoSmithKline, the largest drug company in Britain and one of the largest in the world, has made an industry first move.
Political powerhouse Texas Right to Life is working overtime to try to defeat a compromise measure aimed at improving state laws governing “end of life” medical decisions. But with time running out to get Senate Bill 303 passed, the fight over the legislation has shifted from political to personal.
Having grown up in a "natural is best" kind of environment, Nathanael Johnson became the family skeptic. His book looks at the polarized viewpoints in a world of "global warming, killer germs, and obesity."
The controversy sparks questions about corporate influence and the new ways we fund journalism.
